FIGURE 2 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies

Tumor profile association with OS. A, Association of OS in tumors with the top 75th percentile of B7-H3 expression (relative to all cancers) across 50 tumor types. *, q < 0.05; **, q < 0.01; ***, q < 0.001. B, OS of patients with high B7-H3 expression compared with low B7-H3 expression (stratified on the basis of medians) for the top six cancers where CD276-high expression is associated with poor OS. Cox proportional HRs were calculated for each comparison group with significance determined as P values of <0.05 using log-rank statistics. C, OS of patients with high B7-H3 expression compared with low B7-H3 expression (stratification based on quartiles) from the start of pembrolizumab treatment for patients with colorectal cancer with microsatellite instability (CRC-MSI-H), NSCLC-adenocarcinoma (NSCLC-Ad) that is PD-L1–positive/EGFR wildtype/ALK wildtype, and NSCLC-squamous (NSCLC-Sq) cell carcinoma that is PD-L1 positive.